Search results for " Guidelines"

showing 10 items of 472 documents

MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management

2016

Abstract Introduction A majority of invasive Candida infections occur in medical wards; however, evidence for management in this setting is scarce and based primarily on the intensive care or surgical setting. On behalf of the Italian Society for Anti-Infective Therapy (SITA) and the Italian Federation of Associations of Hospital Doctors on Internal Medicine (FADOI), the MEDICAL group produced practical management algorithms for patients in internal medicine wards. Methods The MEDICAL group panel, composed of 30 members from internal medicine, infectious disease, clinical pharmacology, clinical microbiology and clinical epidemiology, provided expert opinion through the RAND/UCLA method. Res…

0301 basic medicineMedical wardAntifungal AgentsConsensusInvasiveCritical CareDelphi TechniqueClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Algorithms; Antifungal Agents; Candidiasis Invasive; Consensus; Critical Care; Delphi Technique; Early Diagnosis; Echinocandins; Humans; Internal Medicine; Italy; Practice Guidelines as Topic; Severity of Illness Index; Internal Medicine030106 microbiologyeducationDelphi methodInvasive candidiasiSettore MED/17 - MALATTIE INFETTIVESeverity of Illness Indexlaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinelawIntensive careSeverity of illnessMedical consensusInternal MedicineMedicineHumansCandidiasis InvasiveClinical severity030212 general & internal medicineRisk stratificationcomputer.programming_languageClinical pharmacologybusiness.industryCandidiasisClinical severity; Invasive candidiasis; Medical wards; Risk stratificationInvasive candidiasismedicine.diseaseMedical wardsInvasive candidiasisEarly DiagnosisItalyInfectious disease (medical specialty)Practice Guidelines as TopicbusinessClinical severity; Invasive candidiasis; Medical wards; Risk stratification; Internal MedicinecomputerAlgorithmDelphiAlgorithms
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

The association between adherence to the New Nordic Diet and diet quality.

2016

Background : Previous studies have reported a positive association between scoring on healthy Nordic diet scales and the intake of healthy foods and nutrients, and also with higher intake of meat, sweets, cakes, and energy in general. These studies have used the same food frequency questionnaire (FFQ) responses for constructing the diet score as for calculating intakes of foods and nutrients. Thus, it is not clear whether the coexistence of healthy and less healthy dietary aspects among adherers to Nordic diets would occur even though separate methods were applied for exploring these relations. Objective : To assess the association between adherence to the New Nordic Diet (NND), derived fro…

0301 basic medicineNew Nordic Dietlcsh:TX341-641NorwegianNutrient intake03 medical and health sciencesNutrientEnvironmental healthMedicineFood scienceFood Related Nutrition030109 nutrition & dieteticsNutrition and Dieteticsnutrient intakebusiness.industryDietary intakePublic Health Environmental and Occupational HealthFood frequency questionnairefood and beveragesdiet scoreNorwegian food-based guidelinesHealthy dietlanguage.human_languageNew Nordic Diet; Diet score; Norwegian food-based guidelines; Dietary intake; Nutrient intakeDiet qualitylanguageOriginal ArticleNutrition researchbusinessdietary intakelcsh:Nutrition. Foods and food supplyFood ScienceFoodnutrition research
researchProduct

Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?

2016

Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scien…

0301 basic medicineOncologyIndolesLung NeoplasmsAngiogenesisInvestigationalangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies; Monoclonal; Carcinoma; Non-Small-Cell Lung; Chemotherapy; Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization; Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies; Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAngiogenesis InhibitorsNSCLCangiogenesischemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMonoclonalDrug DiscoverynintedanibdocetaxelNon-Small-Cell LungAdjuvantNeovascularization PathologicTherapies InvestigationalAntibodies MonoclonalDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicAdenocarcinomaTaxoidsNintedanibAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabramucirumabProtein Kinase InhibitorAntibodies Monoclonal HumanizedAntibodiesRamucirumab03 medical and health sciencesTaxoidInternal medicinemedicineChemotherapyHumansProtein Kinase InhibitorsNeovascularizationPathologicPharmacologyPerformance statusbusiness.industryDrug Discovery3003 Pharmaceutical ScienceCarcinomaangiogenesiCancermedicine.diseaseLung Neoplasm030104 developmental biologychemistryIndoleTherapiesangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies Monoclonal; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistrybusinessExpert Opinion on Biological Therapy
researchProduct

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

2018

Abstract Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. Materials and methods A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2, Day 1), gemcitabine (1250 mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles, followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested, 150 mg twice daily (bid) and 200 mg bid, to determine…

0301 basic medicineOncologyMaleCancer ResearchPHARMACOKINETICSIndolesLung NeoplasmsPACLITAXELDeoxycytidineANGIOGENESISSquamouschemistry.chemical_compound0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsBIBF 1120Aged 80 and overMiddle AgedPrognosisTreatment OutcomeOncologyPaclitaxelLABEL DOSE-ESCALATION030220 oncology & carcinogenesisNintedanibFemaleCLINICAL-PRACTICE GUIDELINESmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyBevacizumabMaximum Tolerated DoseNintedanibBEVACIZUMABCONTROLLED-TRIALDisease-Free Survival03 medical and health sciencesPharmacokineticsInternal medicinemedicineHumansAdverse effectAgedNeoplasm StagingTRIPLE ANGIOKINASE INHIBITORCisplatinCARBOPLATINbusiness.industryGemcitabineCarboplatinGemcitabine030104 developmental biologychemistryCisplatinbusinessLung Cancer
researchProduct

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German …

2020

Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects. Objectives Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possib…

0301 basic medicineOncologymedicine.medical_specialtyAntifungal Agents030106 microbiologyMedizinDermatologyNeutropeniaAspergillosis030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineHumansHematologybusiness.industryMucormycosisCancerGeneral MedicineGuidelineEvidence-based medicineHematologymedicine.diseaseClinical trialInfectious DiseasesHematologic NeoplasmsPractice Guidelines as TopicbusinessInvasive Fungal InfectionsAgranulocytosis
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Guidelines for the use of flow cytometry and cell sorting in immunological studies

2017

The marriage between immunology and cytometry is one of the most stable and productive in the recent history of science. A rapid search in PubMed shows that, as of July 2017, using “flow cytometry immunology” as a search term yields more than 68 000 articles, the first of which, interestingly, is not about lymphocytes. It might be stated that, after a short engagement, the exchange of the wedding rings between immunology and cytometry officially occurred when the idea to link fluorochromes to monoclonal antibodies came about. After this, recognizing different types of cells became relatively easy and feasible not only by using a simple fluorescence microscope, but also by a complex and some…

0301 basic medicineT-LymphocytesCell SeparationT cell precursors0302 clinical medicineImmunophenotypingHuman lymphopoiesis[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyImmunology and AllergyNon-U.S. Gov'tImmunologic Techniquemedicine.diagnostic_testResearch Support Non-U.S. Gov'tvirus diseaseshemic and immune systemsFalse Positive ReactionCell sortingFlow Cytometrynatural killer and innate lymphoid cells differentiation3. Good healthResearch Design[SDV.IMM]Life Sciences [q-bio]/ImmunologyHumanQuality Controlmedicine.drug_classImmunologyAnimals; Cell Proliferation; Cell Separation; DNA; False Positive Reactions; Flow Cytometry; Humans; Immunophenotyping; Quality Control; RNA; Research Design; Software; T-Lymphocytes; Guidelines as Topic; Immunologic Techniques; Immunology and Allergy; Immunologychemical and pharmacologic phenomenaGuidelines as TopicComputational biologyBiologyMonoclonal antibodyResearch SupportArticleFlow cytometryImmunophenotypingN.I.H.03 medical and health sciencesImmune systemImmunologic TechniqueResearch Support N.I.H. Extramuralmedicineearly lymphoid progenitorsJournal ArticleAnimalsHumansMass cytometryFalse Positive ReactionsImmunology and Allergy; Immunology; Flow cytometryIMUNOLOGIACell ProliferationAnimalExtramuralB cell ontogenyDNA030104 developmental biologyT-LymphocyteImmunologic TechniquesRNACytometrySoftware030215 immunologyEuropean Journal of Immunology
researchProduct

Clinical Guide and Update on Porphyrias.

2019

Physicians should be aware of porphyrias, which could be responsible for unexplained gastrointestinal, neurologic, or skin disorders. Despite their relative rarity and complexity, most porphyrias can be easily defined and diagnosed. They are caused by well-characterized enzyme defects in the complex heme biosynthetic pathway and are divided into categories of acute vs non-acute or hepatic vs erythropoietic porphyrias. Acute hepatic porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) manifest in attacks and are characterized by overproduction of porphyrin precursors, producing often serious abdomin…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPorphyrinsGastrointestinal DiseasesVariegate porphyriaPorphobilinogenCongenital erythropoietic porphyriaGastroenterologySkin Diseases03 medical and health sciencesPorphyrias0302 clinical medicineInternal medicinemedicineHumansPorphyria cutanea tardaskin and connective tissue diseasesAcute intermittent porphyriaHepatologybusiness.industryHepatoerythropoietic porphyriaGastroenterologynutritional and metabolic diseasesAminolevulinic Acidmedicine.disease030104 developmental biologyHereditary coproporphyriaPorphyriaPractice Guidelines as Topic030211 gastroenterology & hepatologyErythropoietic protoporphyriaNervous System DiseasesbusinessGastroenterology
researchProduct

Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH sur…

2017

Background Scant information is available about how transplant centers are managing their use of quantitative molecular testing (QNAT) assays for active cytomegalovirus (CMV) infection monitoring in solid organ transplant (SOT) recipients. The current study was aimed at gathering information on current practices in the management of CMV infection across European centers in the era of molecular testing assays. Methods A questionnaire-based cross-sectional survey study was conducted by the European Study Group of Infections in Immunocompromised Hosts (ESGICH) of the Society of Clinical Microbiology and Infectious Diseases (ESCMID). The invitation and a weekly reminder with a personal link to …

0301 basic medicinecytomegalovirus; solid organ transplantation; survey.cytomegalovirus ; solid organ transplantation ; surveyCross-sectional studyCytomegalovirusTransplantsPractice Patterns030230 surgeryOrgan transplantationlaw.invention0302 clinical medicinePostoperative Complicationslaw03.02. Klinikai orvostanViralPractice Patterns Physicians'solid organ transplantationPolymerase chain reactionViral LoadEuropeInfectious DiseasesCytomegalovirus InfectionsPractice Guidelines as Topiccytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral LoadGuideline Adherencecytomegalovirus; solid organ transplantation; survey; Antibiotic Prophylaxis; Antiviral Agents; Cross-Sectional Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA Viral; Europe; Guideline Adherence; Health Care Surveys; Humans; Immunocompromised Host; Immunosuppression; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns Physicians'; Real-Time Polymerase Chain Reaction; Transplant Recipients; Transplants; Viral Load; Transplantation; Infectious Diseasesmedicine.medical_specialty030106 microbiologyCongenital cytomegalovirus infectionReal-Time Polymerase Chain ReactionAntiviral Agents03 medical and health sciencesImmunocompromised HostmedicineHumanssurveyIntensive care medicineImmunosuppression TherapyTransplantationPhysicians'business.industryDNAOrgan TransplantationAntibiotic Prophylaxismedicine.diseaseMolecular diagnosticsTransplant RecipientsCytomegalovirus infectionTransplantationcytomegalovirus; solid organ transplantation; survey; Transplantation; Infectious DiseasesCross-Sectional StudiesCytomegalovirus; Solid organ transplantation; Survey; Transplantation; Infectious DiseasesHealth Care SurveysDNA ViralImmunologySolid organ transplantationbusinessImmunosuppression
researchProduct